この記事を読む

T細胞エンゲ―ジャー、第Ⅱ相でも有望な結果

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. Ahn MJ et al.N Engl J Med. 2023 Nov 30;389(22):2…

この記事を読む

Exon20挿入変異に対するアミバンタマブ+抗がん剤、注入反応とスケジュールが問題?

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. Zhou CN Engl J Med. 2023 Oct 21. Epub ahead of prin…

この記事を読む

PS不良、臨床試験に適さない患者への免疫療法

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligi…

この記事を読む

初回治療としてのセルぺルカチニブ

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. Zhou C et al.N Engl J Med. 2023…

この記事を読む

FLAURA2: 抗がん剤+オシメルチニブまずPFS優越を証明

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. Planchard D et al.N Engl J Med. 2023 Nov 8.Epub…

この記事を読む

高齢者免疫療法の予後予測

Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD…

この記事を読む

ロルラチニブとALKバリアント3

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Typ…

この記事を読む

免疫療法後は何をしても変わらない?

Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens…

この記事を読む

オシメルチニブとアファチニブ交替療法、耐性機序が興味深い

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single…

この記事を読む

肺炎のような粘液性肺腺癌の元は孤発型なのか?

Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics. Goto E et…